APGE
Apogee Therapeutics, Inc.·Healthcare
86.27
0.289%(−0.25)
Market ClosedLast Updated: — ET
52W L: $31.2152W H: $88.35
APGE NEWS
defenseworld.net
1d ago
Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE
Aberdeen Group plc lessened its stake in Apogee Therapeutics Inc. (NASDAQ: APGE) by 34.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,103 shares of the company's stock after selling 18,657 shares during the quarter. Aberdeen Group plc owned approximately 0.05% of Apogee Therapeutics
globenewswire.com
Mar 26
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
fool.com
Mar 26
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors
The CEO of Apogee Therapeutics reported selling 20,000 shares of the company for approximately $1.50 million on March 11, 2026. This disposition represented 1.71% of Henderson's direct holdings at the time of the transaction, as reported in the Form 4.
defenseworld.net
Mar 26
Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High – Here’s Why
Shares of Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $85.04 and last traded at $78.53, with a volume of 3533056 shares changing hands. The stock had previously closed at $73.00. More Apogee Therapeutics News Here are the
globenewswire.com
Mar 24
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $350 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. The offering is expected to close on March 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters an option for a period of 30 days to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
zacks.com
Mar 24
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.
